The crypto market is massive, and there are many different types of cryptocurrencies you can buy. Ethereum and Solana are smart contract platforms, and XRP is a payments coin, among others. Bitcoin is so large that it has effectively created its own category. You may want to invest in several types to build a diverse crypto portfolio, and with most of the market going through a downturn, now is a ...
The crypto market is massive, and there are many different types of cryptocurrencies you can buy. Ethereum and Solana are smart contract platforms, and XRP is a payments coin, among others. Bitcoin is so large that it has effectively created its own category. You may want to invest in several types to build a diverse crypto portfolio, and with most of the market going through a downturn, now is a good time to buy the dip. However, you're better off avoiding one popular type of cryptocurrency: meme coins. Image source: Getty Images. Continue reading
Photo Italia LLC/iStock Editorial via Getty Images Just a couple of days ago, I finished an analysis of Greene County Bancorp ( GCBC ). I rated the stock as a Buy based on its strong earnings growth, credit quality, and operational metrics. My research piqued my curiosity about other small-cap banks in the area and led me to learn more about Arrow Financial Corporation ( AROW ). With a gain of ove...
Photo Italia LLC/iStock Editorial via Getty Images Just a couple of days ago, I finished an analysis of Greene County Bancorp ( GCBC ). I rated the stock as a Buy based on its strong earnings growth, credit quality, and operational metrics. My research piqued my curiosity about other small-cap banks in the area and led me to learn more about Arrow Financial Corporation ( AROW ). With a gain of over 22% in the last 12 months, AROW has certainly made some meaningful improvements to its bottom line in the last year that have caught the market’s attention. Its Q4 2025 results included a record net income of $14 million, or $0.85 per share. A deeper dive into the company’s operations, however, paints a noticeable contrast to many of the positives that I saw in GCBC. Several of Arrow's key barometers for performance fall short of the usual standards I want to see in a small-cap bank before deeming it a Buy. The company also recently made an offer to acquire privately held Adirondack Bancorp in a deal that is valued at about $89 million . Reading through the terms of the deal and the assets that AROW will acquire did not spark any new enthusiasm on my end. I consider Arrow Financial to be a Hold for the reasons discussed below. Company Overview With a geographic footprint of 38 branches in Northeast New York, Arrow Financial is the holding company for Arrow Bank. Formerly operating under the names Glens Falls National Bank and Trust Company and Saratoga National Bank and Trust Company, Arrow is a full-service commercial bank that also offers wealth management and insurance services to its communities. In 2024, it was named to Piper Sandler’s Small-Cap All-Stars, a list of high-quality banks that included Greene County Bancorp in 2025. AROW has a current market cap of $550.2 million. According to its 2025 10-K filing , the company controlled $4.45 billion in assets at the end of last year, including a loan portfolio worth $3.45 billion. The bank’s total gross loans only gre...
The US Justice Department has settled for roughly US$1.2 million a lawsuit from Michael Flynn, the former national security adviser to US President Donald Trump who pleaded guilty during the Republican’s first term to lying to the FBI about his conversations with a top Russian diplomat and was later pardoned. Court papers filed on Wednesday do not reveal the settlement amount, but a person familia...
The US Justice Department has settled for roughly US$1.2 million a lawsuit from Michael Flynn, the former national security adviser to US President Donald Trump who pleaded guilty during the Republican’s first term to lying to the FBI about his conversations with a top Russian diplomat and was later pardoned. Court papers filed on Wednesday do not reveal the settlement amount, but a person familiar with the matter, who spoke to Associated Press on condition of anonymity to disclose nonpublic...
Investors looking for solid dividend-paying stocks with high yields can find them in a variety of industries. Let's look at five you can buy right now. British American Tobacco (NYSE: BTI) is a high-yield stock in the defensive tobacco industry that is starting to gain momentum. Its smokeless portfolio is becoming a larger part of its business, now representing more than 18% of its overall revenue...
Investors looking for solid dividend-paying stocks with high yields can find them in a variety of industries. Let's look at five you can buy right now. British American Tobacco (NYSE: BTI) is a high-yield stock in the defensive tobacco industry that is starting to gain momentum. Its smokeless portfolio is becoming a larger part of its business, now representing more than 18% of its overall revenue, as its Velo Plus nicotine pouches are seeing extraordinary growth. Its cigarette business continues to see volume declines, but strong pricing power continues to deliver overall revenue growth. At the same time, the company is in the process of deleveraging its balance sheet and is on track to reduce its leverage to between 2 to 2.5 times by the end of the year. This makes it a solid dividend stock to own. Continue reading
Shishin Maxim, the chief information officer of CorVel (NASDAQ:CRVL) , reported the exercise and immediate sale of 2,400 shares of common stock for a total transaction value of approximately $130,000 on March 16, 2026, according to a SEC Form 4 filing . Transaction value based on SEC Form 4 weighted average purchase price ($54.00); post-transaction value based on March 16, 2026 market close ($54.0...
Shishin Maxim, the chief information officer of CorVel (NASDAQ:CRVL) , reported the exercise and immediate sale of 2,400 shares of common stock for a total transaction value of approximately $130,000 on March 16, 2026, according to a SEC Form 4 filing . Transaction value based on SEC Form 4 weighted average purchase price ($54.00); post-transaction value based on March 16, 2026 market close ($54.00). CorVel Corporation is a leading provider of technology-enabled healthcare management and insurance solutions, with a focus on cost containment and process optimization for claims. The company leverages advanced analytics and automation to deliver efficient, scalable services to a diverse client base. Its strategic emphasis on innovation and operational efficiency supports its competitive position in the insurance services sector. Continue reading
(RTTNews) - The South Korea stock market has climbed higher in back-to-back sessions, gaining almost 240 points or 4.4 percent along the way. The KOSPI now sits just above the 5,640-point plateau and it's tipped to open in the green again on Thursday.
(RTTNews) - The South Korea stock market has climbed higher in back-to-back sessions, gaining almost 240 points or 4.4 percent along the way. The KOSPI now sits just above the 5,640-point plateau and it's tipped to open in the green again on Thursday.
ROCKVILLE, Md. and SUZHOU, China, March 25, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred hereinto as “Ascentage Pharma,” the “Company,” “we,” “us” or “our”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to addres...
ROCKVILLE, Md. and SUZHOU, China, March 25, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred hereinto as “Ascentage Pharma,” the “Company,” “we,” “us” or “our”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today reported its unaudited financial results for the year ended December 31, 2025, and provided updates on key ongoing clinical programs and commercial activities.
INVESTOR NOTICE: Oracle Corporation (ORCL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces Business Wire
INVESTOR NOTICE: Oracle Corporation (ORCL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces Business Wire
Explore the exciting world of Tetra Tech (NASDAQ: TTEK) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Feb. 4, 2026. The video was published on March 25, 2026. Continue reading
Explore the exciting world of Tetra Tech (NASDAQ: TTEK) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Feb. 4, 2026. The video was published on March 25, 2026. Continue reading
INVESTOR NOTICE: Oracle Corporation (ORCL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces Carroll County Mirror-Democrat
INVESTOR NOTICE: Oracle Corporation (ORCL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces Carroll County Mirror-Democrat
INVESTOR NOTICE: Oracle Corporation (ORCL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces mydailyrecord.com
INVESTOR NOTICE: Oracle Corporation (ORCL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces mydailyrecord.com
INVESTOR NOTICE: Oracle Corporation (ORCL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces The Norfolk Daily News
INVESTOR NOTICE: Oracle Corporation (ORCL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces The Norfolk Daily News
INVESTOR NOTICE: Oracle Corporation (ORCL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces businesswire.com
INVESTOR NOTICE: Oracle Corporation (ORCL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces businesswire.com
Latest strike brings number of deaths to at least 163 since attacks on alleged ‘narco-terrorists’ began in September The US has launched another strike on a vessel in the Caribbean, killing four people, the US Southern Command said. The command which oversees combatant operations in Latin America and the Caribbean announced on X that it had conducted a “lethal kinetic strike on a vessel operated b...
Latest strike brings number of deaths to at least 163 since attacks on alleged ‘narco-terrorists’ began in September The US has launched another strike on a vessel in the Caribbean, killing four people, the US Southern Command said. The command which oversees combatant operations in Latin America and the Caribbean announced on X that it had conducted a “lethal kinetic strike on a vessel operated by Designated Terrorist Organizations”. Continue reading...
Earnings Call Insights: Precigen, Inc. (PGEN) Q4 2025 Management View Helen Sabzevari, President and CEO, highlighted the company's transformation to a "product revenue-generating commercial biotech company" following the full FDA approval and commercial launch of PAPZIMEOS, the first therapeutic for adult recurrent respiratory papillomatosis (RRP). She reported, "net product revenue for Q4 2025 w...
Earnings Call Insights: Precigen, Inc. (PGEN) Q4 2025 Management View Helen Sabzevari, President and CEO, highlighted the company's transformation to a "product revenue-generating commercial biotech company" following the full FDA approval and commercial launch of PAPZIMEOS, the first therapeutic for adult recurrent respiratory papillomatosis (RRP). She reported, "net product revenue for Q4 2025 was $3.4 million, with shipments commencing in November" and stated, "we expect revenues in Q1 to exceed $18 million." Sabzevari emphasized PAPZIMEOS' "broad label for adult RRP with no restriction based on the number of prior surgeries" and underscored its "unmatched efficacy" and "durable ongoing responses," citing more than three years of follow-up in clinical studies. She noted a consensus paper published by 16 leading U.S. physicians recommending PAPZIMEOS as the "preferred first-line treatment for adults with recurrent respiratory papillomatosis." Phil Tennant, Chief Commercial Officer, described the rapid expansion of payer coverage, stating, "In early January, we had approximately 170 million lives covered, which has now increased to approximately 215 million, including nearly all major payers across commercial, Medicare and Medicaid." Tennant reported over 300 patients in the Precigen patient support hub and observed, "Brand utilization is accelerating across the country in both the large institutions and academic centers as well as in the community setting." Harry Thomasian, Chief Financial Officer, stated, "Revenue for the year totaled $9.7 million versus $3.9 million in 2024, resulting in an increase of $5.8 million or 149%." He added, "We expect revenue for Q1 of 2026 will exceed $18 million." Thomasian also noted, "Our net loss attributable to common shareholders was $429.6 million, or $1.37 per share for the year ended December 31, 2025," with two large noncash items totaling $318.5 million or $1.02 per share, which "will not recur in the future." Sabzevari an...